文献速递肝病

索磷布韦/维帕他韦联合或不联合伏西瑞韦治疗初治慢性丙型肝炎的患者报告结局:来自POLARIS 2和3研究

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-27

基于POLARIS-2和POLARIS-3两项临床试验中1160例未接受过直接抗病毒药物治疗的慢性丙型肝炎患者,评估索磷布韦/维帕他韦(SOF/VEL)联合或不联合伏西瑞韦(VOX)对患者报告结局的影响。治疗期间多数患者报告结局评分显著改善,停药后至随访第24周获得显著且有临床意义的改善,且两种方案间无显著差异。

要点

  • 治疗期间多数患者报告结局评分显著改善,平均提高2.3至15.0分(0-100量表)。
  • 停药后至随访第12周和第24周,患者报告结局获得显著且有临床意义的改善。
  • 抑郁、焦虑和肝硬化是患者报告结局受损的独立预测因素,治疗方案选择与患者报告结局无显著关联。

核心结论

  • SOF/VEL联合或不联合VOX的全基因型方案不仅疗效和安全性良好,还能在治疗期间及获得持续病毒学应答后显著改善初治丙型肝炎患者的体验。

研究设计与样本

  • 研究收集了POLARIS-2和POLARIS-3临床试验中未接受过直接抗病毒药物治疗、涵盖所有HCV基因型的参与者的患者报告结局数据,共1160例患者,其中611例接受SOF/VEL/VOX,549例接受SOF/VEL。
  • 参与者在基线、治疗期间和随访期间自行填写SF-36v2、FACIT-F、CLDQ-HCV和WPAI:SHP量表。

主要发现

  • 患者平均年龄52.8±11.0岁,男性占55.9%,初治患者占75.4%,肝硬化患者占33.9%。
  • 持续病毒学应答率(SVR12)为95%-98%。
  • 治疗期间多数患者报告结局评分显著改善(除一项外所有P<.01),至治疗结束时平均提高2.3至15.0分(0-100量表)。
  • SOF/VEL/VOX组与SOF/VEL组的改善程度相似(所有P>.05)。
  • 停药后,两种方案治疗的患者均获得显著且有临床意义的患者报告结局改善(治疗后第12周提高2.7至16.7分,第24周提高3.9至20.1分;除一项外所有P<.001)。

临床怎么用

  • 作者认为,SOF/VEL联合或不联合VOX的全基因型方案不仅疗效和安全性良好,还能在治疗期间及获得持续病毒学应答后显著改善初治丙型肝炎患者的体验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis C infection leads to impairment of patient-reported outcomes (PROs). Treatment with direct-acting antiviral regimens results in short- and long-term improvement of these outcomes. AIM: To assess PROs in patients treated with a newly developed direct-acting antiviral, a fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) with/without voxilaprevir (VOX). METHODS: The PRO data were collected from participants of POLARIS-2 and POLARIS-3 clinical trials (DAA-naïve, all HCV genotypes). Participants self-administered SF-36v2, FACIT-F, CLDQ-HCV and WPAI:SHP instruments at baseline, during treatment, and in follow-up. RESULTS: Of 1160 patients, 611 received SOF/VEL/VOX and 549 received SOF/VEL (52.8 ± 11.0 years, 55.9% male, 75.4% treatment-naïve, 33.9% cirrhotic). The sustained viral response at 12 weeks (SVR12) rates were 95%-98%. During treatment, improvements in most PRO scores were significant (all but one P < .01) and ranged from, on average, +2.3 to +15.0 points (on a 0-100 scale) by the end of treatment. These improvements were similar between SOF/VEL/VOX and SOF/VEL arms (all P > .05). After treatment discontinuation, patients treated with both regimens achieved significant and clinically meaningful PRO gains (+2.7 to +16.7 by post-treatment week 12, +3.9 to +20.1 by post-treatment week 24; all but one P < .001). Multivariate analysis showed that depression, anxiety and cirrhosis were the most consistent independent predictors of PRO impairment while no association of PROs with the treatment regimen choice was found (all P > .05). CONCLUSIONS: The pan-genotypic regimens with SOF/VEL with or without VOX not only have excellent efficacy and safety, but also significantly positively impact patients' experience both during treatment and after achieving sustained virologic response in DAA-naïve patients with HCV.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Jacobson IM, et al. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. Aliment Pharmacol Ther. 2017. PMID: 29181842. doi:10.1111/apt.14423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。